Breakthrough in Alzheimer's Research: A Bacterial Protein Could Hold the Key to Treatment

In a surprise twist, researchers have discovered that a protein from Helicobacter pylori, a bacterium commonly associated with stomach ulcers, can block the toxic buildup of amyloid-beta and tau proteins, which are central to Alzheimer's disease. This finding could potentially lead to a new strategy for treating the condition, which affects millions worldwide. The research, led by Associate Professor Gefei Chen at the Karolinska Institutet, used computer modeling and nuclear magnetic resonance to understand how the protein fragment, called CagAN, interacts with amyloid-beta and tau.

Key Takeaways:

• The protein fragment, CagAN, from Helicobacter pylori has been shown to significantly reduce the formation of amyloid-beta and tau aggregates in the lab, suggesting potential therapeutic applications for Alzheimer's disease.
• CagAN has been found to block the aggregation of amyloid-beta and tau, which are hallmarks of Alzheimer's disease, using a novel mechanism that prevents the proteins from coming together to form clumps.
• The research suggests that a single bacterial fragment could interfere with multiple toxic proteins involved in different diseases, including Alzheimer's, type 2 diabetes, and Parkinson's disease, by disrupting the shared mechanism of amyloid protein aggregation.
• While the research is still at an early stage, the findings open a new path for potential treatments and raise questions about the beneficial properties of a bacterium often seen as solely harmful.
• A more precise and personalized approach to understanding the interactions between microorganisms and the human body may be necessary, rather than aiming to eliminate all microbes with antibiotics.

Statistics:

• Every three seconds, someone in the world develops dementia.
• Alzheimer's disease accounts for between 60 per cent and 70 per cent of all dementia cases.
• The current treatments that aim to clear amyloid-beta from the brain only work in the early stages of the disease and may cause serious side effects.
• The CagAN protein fragment was found to almost completely stop amyloid-beta from forming amyloid aggregates at very low concentrations.

Sources:

• The Conversation article by Gefei Chen
• The article is republished from The Conversation under a Creative Commons license. Read the original article .